OBJECTIVE： To observe the clinical efficacy and safety of beraprost combined with fibrinogenase in the treatment of lower extremity atherosclerotic occlusive disease （LEAOD）. METHODS： A total of 82 LEAOD patients selected from our hospital during Jan. 2015-Jan. 2016 were divided into control group and observation group according to random number table， with 41 cases in each group. All patients received low salt and low fat diet on the basis of treatment for primary disease. Control group was additionally given Fibrinogenase injection 200 U， ivgtt， qd； observation group was additionally given Beraprost sodium tablets 40 μg，tid， after meal， on the basis of control group. Both groups were treated for 15 d. Clinical efficacies as well as hemorheological indexes， ankle-brachial indexes， pain scores， cold felling scores， intermittent claudication scores and serum oxidation stress indexes before and after treatment were compared between 2 groups. The occurrence of ADR was also recorded. RESULTS： Total response rate of observation group （90.24％） was significantly higher than that of control group （78.05％）， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in above indexes between 2 groups （P＞0.05）. Compared to before treatment， whole blood high shear viscosity， plasma viscosity， hematocrit， fibrinogen contents， platelet adhesion rates， pain scores， cold feeling scores， intermittent claudication scores and serum MDA levels of 2 groups were decreased significantly after treatment； while ankle-brachial indexes， the serum levels of SOD， T-AOC and GSH-Px were increased； the indexes of observation group were better than those of control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Beraprost combined with fibrinogenase show good therapeutic efficacy for LEAOD， can effectively relieve clinical symptoms， promote local blood circulation and improve oxidant stress level with good safety.